Drug intelligence / Profile preview

levamisole + budesonide + formoterol

Development stage
Discontinued
Lead developer
AstraZeneca
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Inhalation
01

Overview

This is a combination drug consisting of three active pharmaceutical ingredients: - **Levamisole** is an immunomodulatory and antihelminthic agent, historically used to treat parasitic worm infections and as an adjunct in some cancer therapies. It acts primarily by modulating the immune response. - **Budesonide** is a synthetic corticosteroid with potent anti-inflammatory properties, commonly used via inhalation for asthma and chronic obstructive pulmonary disease (COPD). It works by reducing inflammation in the airways. - **Formoterol** is a long-acting beta2-adrenergic agonist (LABA) bronchodilator that relaxes airway smooth muscle, leading to bronchodilation and improved airflow. There are no known approved or marketed products containing this exact triple combination. Budesonide plus formoterol is widely available as a fixed-dose inhaler for asthma and COPD under brand names such as Symbicort[1][5][6][7][8]. Levamisole has been used separately for other indications but not typically combined with these agents in clinical practice.

02

Targets

ADRB2 (β2)GR (Glucocorticoid receptor)PLpro (Papain-like protease)

Beyond the preview

Go deeper on levamisole + budesonide + formoterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levamisole + budesonide + formoterol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call